Literature DB >> 18085644

The artificial surface-induced whole blood inflammatory reaction revealed by increases in a series of chemokines and growth factors is largely complement dependent.

K T Lappegård1, G Bergseth, J Riesenfeld, A Pharo, P Magotti, J D Lambris, T E Mollnes.   

Abstract

Exposing blood to an artificial surface results in a systemic inflammatory response, including cytokine release and complement activation. We studied the artificial surface-induced inflammation in human whole blood using an extensive panel of inflammatory mediators including proinflammatory cytokines, chemokines and growth-factors and investigated the role of the complement system in the induction of this response. Using multiplex technology, 27 different inflammatory mediators were measured after circulating blood for 4 hours in polyvinyl chloride tubing. The C3 inhibitor compstatin was used to block complement activation. A significant (p < 0.05) increase in 14 of the 27 mediators was induced by the surface, of which 7 were chemokines (IL-8, MCP-1, MIP-1alpha, MIP-1beta, RANTES, eotaxin and IP-10) and 5 were growth-factors (G-CSF, GM-CSF, VEGF, PDGF and FGF). The traditional proinflammatory cytokines like IL-1beta, TNFalpha and IL-6 were not induced, although IL-6, as well as IL-15 and IL-17 increased if the surface was coated with highly bioincompatible laminaran. Inhibition of complement activation with compstatin significantly (p < 0.05) reduced the formation of 12 of the 14 mediators. For 10 of the 12 mediators, the inhibition was by 2/3 or more, for the remaining two the inhibition was more moderate. A highly biocompatible heparin-coated PVC surface was used as negative control and completely abolished the whole inflammatory response. The artificial surface PVC markedly induced a broad spectrum of chemokines and growth-factors, which was largely dependent on activation of complement.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18085644      PMCID: PMC2814839          DOI: 10.1002/jbm.a.31750

Source DB:  PubMed          Journal:  J Biomed Mater Res A        ISSN: 1549-3296            Impact factor:   4.396


  20 in total

1.  Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation.

Authors:  C S Rinder; H M Rinder; B R Smith; J C Fitch; M J Smith; J B Tracey; L A Matis; S P Squinto; S A Rollins
Journal:  J Clin Invest       Date:  1995-09       Impact factor: 14.808

2.  Complement activation during cardiopulmonary bypass: effects of immobilized heparin.

Authors:  M Pekna; L Hagman; E Haldén; U R Nilsson; B Nilsson; S Thelin
Journal:  Ann Thorac Surg       Date:  1994-08       Impact factor: 4.330

3.  Heparin-coated cardiopulmonary bypass circuits reduce circulating complement factors and interleukin-6 in paediatric heart surgery.

Authors:  C Olsson; A Siegbahn; A Henze; B Nilsson; P Venge; P O Joachimsson; S Thelin
Journal:  Scand Cardiovasc J       Date:  2000       Impact factor: 1.589

4.  Pharmacology and biological efficacy of a recombinant, humanized, single-chain antibody C5 complement inhibitor in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass.

Authors:  J C Fitch; S Rollins; L Matis; B Alford; S Aranki; C D Collard; M Dewar; J Elefteriades; R Hines; G Kopf; P Kraker; L Li; R O'Hara; C Rinder; H Rinder; R Shaw; B Smith; G Stahl; S K Shernan
Journal:  Circulation       Date:  1999 Dec 21-28       Impact factor: 29.690

5.  Essential role of the C5a receptor in E coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation.

Authors:  Tom Eirik Mollnes; Ole-Lars Brekke; Michael Fung; Hilde Fure; Dorte Christiansen; Grethe Bergseth; Vibeke Videm; Knut Tore Lappegård; Jörg Köhl; John D Lambris
Journal:  Blood       Date:  2002-09-01       Impact factor: 22.113

6.  Optimal heparin surface concentration and antithrombin binding capacity as evaluated with human non-anticoagulated blood in vitro.

Authors:  Jonas Andersson; Javier Sanchez; Kristina Nilsson Ekdahl; Graciela Elgue; Bo Nilsson; Rolf Larsson
Journal:  J Biomed Mater Res A       Date:  2003-11-01       Impact factor: 4.396

7.  Artificial surface-induced cytokine synthesis: effect of heparin coating and complement inhibition.

Authors:  Knut Tore Lappegård; Michael Fung; Grethe Bergseth; Johan Riesenfeld; Tom Eirik Mollnes
Journal:  Ann Thorac Surg       Date:  2004-07       Impact factor: 4.330

8.  Effect of complement inhibition and heparin coating on artificial surface-induced leukocyte and platelet activation.

Authors:  Knut Tore Lappegård; Michael Fung; Grethe Bergseth; Johan Riesenfeld; John D Lambris; Vibeke Videm; Tom Eirik Mollnes
Journal:  Ann Thorac Surg       Date:  2004-03       Impact factor: 4.330

9.  Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex.

Authors:  T E Mollnes; T Lea; S S Frøland; M Harboe
Journal:  Scand J Immunol       Date:  1985-08       Impact factor: 3.487

10.  Heparin-coated equipment reduces complement activation during cardiopulmonary bypass in the pig.

Authors:  L Nilsson; K E Storm; S Thelin; L Bagge; J Hultman; J Thorelius; U Nilsson
Journal:  Artif Organs       Date:  1990-02       Impact factor: 3.094

View more
  10 in total

Review 1.  Compstatin: a complement inhibitor on its way to clinical application.

Authors:  Daniel Ricklin; John D Lambris
Journal:  Adv Exp Med Biol       Date:  2008       Impact factor: 2.622

2.  Artificial surface-induced inflammation relies on complement factor 5: proof from a deficient person.

Authors:  Grethe Bergseth; John D Lambris; Tom Eirik Mollnes; Knut Tore Lappegård
Journal:  Ann Thorac Surg       Date:  2011-02       Impact factor: 4.330

3.  Extensive adhesion formation in a total knee replacement in the setting of a gastrointestinal stromal tumor: A case report.

Authors:  Steven Mitchell; Anderson Lee; Ryan Stenquist; David Yatsonsky Ii; Megan L Mooney; Vithal B Shendge
Journal:  World J Orthop       Date:  2022-05-18

Review 4.  Targeted complement inhibition as a promising strategy for preventing inflammatory complications in hemodialysis.

Authors:  Robert A DeAngelis; Edimara S Reis; Daniel Ricklin; John D Lambris
Journal:  Immunobiology       Date:  2012-11       Impact factor: 3.144

5.  Development of post-pericardiotomy syndrome is preceded by an increase in pro-inflammatory and a decrease in anti-inflammatory serological markers.

Authors:  Nora Snefjellå; Knut Tore Lappegård
Journal:  J Cardiothorac Surg       Date:  2012-07-23       Impact factor: 1.637

6.  Improved ex vivo blood compatibility of central venous catheter with noble metal alloy coating.

Authors:  Manijeh Vafa Homann; Dorota Johansson; Håkan Wallen; Javier Sanchez
Journal:  J Biomed Mater Res B Appl Biomater       Date:  2015-07-06       Impact factor: 3.368

7.  Iron oxide nanoparticles induce cytokine secretion in a complement-dependent manner in a human whole blood model.

Authors:  Susann Wolf-Grosse; Anne Mari Rokstad; Syed Ali; John D Lambris; Tom E Mollnes; Asbjørn M Nilsen; Jørgen Stenvik
Journal:  Int J Nanomedicine       Date:  2017-05-23

8.  In Vitro and In Vivo Biocompatibility Evaluation of Polyallylamine and Macromolecular Heparin Conjugates Modified Alginate Microbeads.

Authors:  Vijayaganapathy Vaithilingam; Bjørg Steinkjer; Liv Ryan; Rolf Larsson; Bernard Edward Tuch; Jose Oberholzer; Anne Mari Rokstad
Journal:  Sci Rep       Date:  2017-09-15       Impact factor: 4.379

Review 9.  Biomarkers in Patients with Left Ventricular Assist Device: An Insight on Current Evidence.

Authors:  Carlotta Sciaccaluga; Nicolò Ghionzoli; Giulia Elena Mandoli; Flavio D'Ascenzi; Marta Focardi; Serafina Valente; Matteo Cameli
Journal:  Biomolecules       Date:  2022-02-19

Review 10.  FGF/FGFR signaling in health and disease.

Authors:  Yangli Xie; Nan Su; Jing Yang; Qiaoyan Tan; Shuo Huang; Min Jin; Zhenhong Ni; Bin Zhang; Dali Zhang; Fengtao Luo; Hangang Chen; Xianding Sun; Jian Q Feng; Huabing Qi; Lin Chen
Journal:  Signal Transduct Target Ther       Date:  2020-09-02
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.